SCHEMBL474897

SCHEMBL474897

Cc1noc(C(C)N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347164 1.00
SCHEMBL1091935 1.00
Hydrochloric Acid SCHEMBL347994 0.98 ACHE (0.34)
Hydrochloric Acid SCHEMBL347993 0.98 ACHE (0.34)
Hydrochloric Acid SCHEMBL21243978 0.98 ACHE (0.34)
Hydrochloric Acid SCHEMBL475087 0.98 ACHE (0.34)
Hydrochloric Acid SCHEMBL346915 0.98 ACHE (0.34)
SCHEMBL15450836 0.83
SCHEMBL4775678 0.82 KDM1A (0.33)
SCHEMBL4775672 0.82 KDM1A (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US disclosed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
EP-4251620-B1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-04-16 EP disclosed
CN-113891745-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
CN-116601149-A Aminoquinazoline derivatives as P2X3 inhibitors 奇斯药制品公司 2023-08-15 CN disclosed
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC 2023-07-13 US disclosed
US-11685736-B2 P2X3 and/or P2X2/3 compounds and methods ABS DEVELOPMENT 1, INC. (US) 2023-06-27 US disclosed
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-03-23 US disclosed
US-20230062975-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS SPRING MILL PHARMA, INC. 2023-03-02 US disclosed
EP-3083619-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS Asana BioSciences, LLC (US) 2016-10-26 EP disclosed
US-20160296501-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC (US) 2016-10-13 US disclosed
WO-2015185485-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2015-12-10 WO disclosed
WO-2015095128-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC (US) 2015-06-25 WO disclosed
EP-2411001-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
EP-2358371-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2011-08-24 EP disclosed
WO-2010111060-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed
EP-2215048-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 EP disclosed
WO-2010051188-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed
WO-2009058299-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 WO disclosed